Mekanisme Resistensi Insulin Terkait Obesitas
Obesity is a condition where excess body fat accumulation occurs. This has become an increasingly progressive problem and the prevalence in Indonesia continues to increase every year. This pathological condition also triggers various metabolic and other non-metabolic disorders. Insulin resistance is one thing that underlies various diseases related to obesity. In obesity, adipocytes experience hypertrophy and will lose their physiological functions. The active products of these two products trigger an increase in the production of Nitric Oxide (NO) and the formation of peroxynitrite derivatives (ONOO), which in turn separates IRS-1 from the activation of PI3K and Akt which are key to translocation of glucose transporters (GLUT4) to the cell surface and activation of glucose transport in glucose myocytes, resulting in insulin resistance. Effective therapy that can be done in obesity is weight loss by doing routine physical activity that can indirectly prevent pathological conditions associated.
Arterburn DE, Maciejewski ML, Tsevat J. Impact of Morbid Obesity on Medical Expenditures in Adults. Int J Obes. 2005; 29:334–9.
Ashraff S, Siddiqui MA, Carline TE. Obesity and Insulin Resistance: Management in Diabetes. Turkish J Endocrinol Metab. 2013; 17(3):57–62.
Borg S, Persson U, Ödegaard K, Berglund G, Nilsson J-Å, Nilsson PM. Obesity, Survival, and Hospital Costs-Findings from a Screening Project in Sweden. Value Heal [Internet]. 2005; 8 (5):562–71.
Available from: http://dx.doi.org/10.1111/j.1524-4733.2005.00048.x
Castro AVB, Kolka CM, Kim SP, Bergman RN. Obesity, Insulin Resistance and Comorbidities - Mechanisms o. 2015;58(6):600–9.
Item F, Konrad D. Visceral Fat, and Metabolic Inflammation: The Portal Theory Revisited. Obes Rev. 2012;13(2):30–9.
Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, et al. Hypertrophy and/or Hyperplasia: Dynamics of Adipose Tissue Growth. PLOS Comput Biol. 2009;5(3).
Khamsin L, Veilleux A, Bergeron S, Marette A. Increased Activation of the Mammalian Target of Rapamycin Pathway in Liver and Skeletal Muscle of Obese Rats: Possible Involvement in obesity-linked Insulin Resistance. Endocrinology. 2005; 146(3):1473–81.
Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.
Marette BA. Molecular Mechanism of Insulin Resistance in Obesity. Off J Int Chair Cardiometabolic Risk. 2008;1(1):5–9.
Prentki M, Nolan CJ. Islet B Cell Failure in Type 2 Diabetes. J Clin Invest. 2006;116(7):1802–12. Salam A. Faktor risiko kejadian obesitas pada remaja. MKMI. 2010; 6(3):185–90.
Tchernof A, Després JP. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359–404.
Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, et al. Overactivation of S6 Kinase 1 as a Cause of Human Insulin Resistance During Increased Amino Acid Availability. 2005; 54:2674–84.
Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A. Activation of The Mammalian Target of Rapamycin Pathway Acutely Inhibits Insulin Signaling to Akt and Glucose Transport in 3T3-L1 and Human Adipocytes. Endocrinology. 2005;146(3):1328–37.
Virtue S, Vidal-Puig A. Adipose Tissue Expandability, Lipotoxicity and The Metabolic Syndrome - An Allostatic Perspective. Biochim Biophys Acta - Mol Cell Biol Lipids [Internet]. 2009;1801(2010):338–49.
Available from: http://dx.doi.org/10.1016/j.bbalip.2009.12.006
Ye J. Role of Insulin in the Pathogenesis of Free Fatty Acid-Induced Insulin Resistance in Skeletal Muscle. Endocrine, Metab Immune Disord Targets. 2012;7(1):65–74.
Copyright (c) 2019 Jurnal Ilmiah Kesehatan Sandi Husada
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.